nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftazidime—SLC22A5—Dactinomycin—sarcoma	0.585	1	CbGbCtD
Ceftazidime—Hallucination—Thiotepa—sarcoma	0.00208	0.00501	CcSEcCtD
Ceftazidime—Injection site pain—Epirubicin—sarcoma	0.00205	0.00494	CcSEcCtD
Ceftazidime—Renal failure—Mitoxantrone—sarcoma	0.00198	0.00476	CcSEcCtD
Ceftazidime—Erythema multiforme—Dactinomycin—sarcoma	0.00196	0.00472	CcSEcCtD
Ceftazidime—Jaundice—Mitoxantrone—sarcoma	0.00196	0.00472	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Etoposide—sarcoma	0.00196	0.00471	CcSEcCtD
Ceftazidime—Flushing—Dactinomycin—sarcoma	0.00193	0.00464	CcSEcCtD
Ceftazidime—Injection site pain—Doxorubicin—sarcoma	0.0019	0.00457	CcSEcCtD
Ceftazidime—Angiopathy—Thiotepa—sarcoma	0.0019	0.00457	CcSEcCtD
Ceftazidime—Immune system disorder—Thiotepa—sarcoma	0.00189	0.00455	CcSEcCtD
Ceftazidime—Agranulocytosis—Mitoxantrone—sarcoma	0.00188	0.00452	CcSEcCtD
Ceftazidime—Bronchospasm—Etoposide—sarcoma	0.00185	0.00444	CcSEcCtD
Ceftazidime—Hallucination—Vincristine—sarcoma	0.00184	0.00444	CcSEcCtD
Ceftazidime—Hyperbilirubinaemia—Epirubicin—sarcoma	0.00184	0.00444	CcSEcCtD
Ceftazidime—Haemoglobin—Mitoxantrone—sarcoma	0.00181	0.00437	CcSEcCtD
Ceftazidime—Haemorrhage—Mitoxantrone—sarcoma	0.00181	0.00435	CcSEcCtD
Ceftazidime—Pancytopenia—Etoposide—sarcoma	0.00178	0.00429	CcSEcCtD
Ceftazidime—Neutropenia—Etoposide—sarcoma	0.00175	0.00422	CcSEcCtD
Ceftazidime—Inflammation—Epirubicin—sarcoma	0.00173	0.00416	CcSEcCtD
Ceftazidime—Vision blurred—Thiotepa—sarcoma	0.00172	0.00413	CcSEcCtD
Ceftazidime—Hyperbilirubinaemia—Doxorubicin—sarcoma	0.00171	0.00411	CcSEcCtD
Ceftazidime—Angiopathy—Vincristine—sarcoma	0.00168	0.00405	CcSEcCtD
Ceftazidime—Vaginal inflammation—Epirubicin—sarcoma	0.00168	0.00404	CcSEcCtD
Ceftazidime—Infestation—Etoposide—sarcoma	0.00167	0.00403	CcSEcCtD
Ceftazidime—Infestation NOS—Etoposide—sarcoma	0.00167	0.00403	CcSEcCtD
Ceftazidime—Agitation—Thiotepa—sarcoma	0.00167	0.00403	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Etoposide—sarcoma	0.00166	0.00399	CcSEcCtD
Ceftazidime—Renal failure—Etoposide—sarcoma	0.00164	0.00396	CcSEcCtD
Ceftazidime—Jaundice—Etoposide—sarcoma	0.00163	0.00393	CcSEcCtD
Ceftazidime—Leukopenia—Thiotepa—sarcoma	0.00163	0.00392	CcSEcCtD
Ceftazidime—Leukopenia—Dactinomycin—sarcoma	0.00162	0.00389	CcSEcCtD
Ceftazidime—Colitis—Epirubicin—sarcoma	0.00161	0.00388	CcSEcCtD
Ceftazidime—Candida infection—Epirubicin—sarcoma	0.0016	0.00385	CcSEcCtD
Ceftazidime—Skin exfoliation—Epirubicin—sarcoma	0.0016	0.00385	CcSEcCtD
Ceftazidime—Inflammation—Doxorubicin—sarcoma	0.0016	0.00385	CcSEcCtD
Ceftazidime—Vaginal infection—Epirubicin—sarcoma	0.00158	0.00381	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Etoposide—sarcoma	0.00158	0.00381	CcSEcCtD
Ceftazidime—Convulsion—Thiotepa—sarcoma	0.00158	0.0038	CcSEcCtD
Ceftazidime—Aplastic anaemia—Epirubicin—sarcoma	0.00157	0.00379	CcSEcCtD
Ceftazidime—Agranulocytosis—Etoposide—sarcoma	0.00156	0.00376	CcSEcCtD
Ceftazidime—Vaginal inflammation—Doxorubicin—sarcoma	0.00155	0.00374	CcSEcCtD
Ceftazidime—Dysgeusia—Mitoxantrone—sarcoma	0.00154	0.00371	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.00154	0.00371	CcSEcCtD
Ceftazidime—Coma—Epirubicin—sarcoma	0.00153	0.00369	CcSEcCtD
Ceftazidime—Colitis—Doxorubicin—sarcoma	0.00149	0.00359	CcSEcCtD
Ceftazidime—Agitation—Vincristine—sarcoma	0.00148	0.00357	CcSEcCtD
Ceftazidime—Vision blurred—Mitoxantrone—sarcoma	0.00148	0.00357	CcSEcCtD
Ceftazidime—Candida infection—Doxorubicin—sarcoma	0.00148	0.00357	CcSEcCtD
Ceftazidime—Skin exfoliation—Doxorubicin—sarcoma	0.00148	0.00357	CcSEcCtD
Ceftazidime—Vaginal infection—Doxorubicin—sarcoma	0.00146	0.00353	CcSEcCtD
Ceftazidime—Nervous system disorder—Thiotepa—sarcoma	0.00146	0.00351	CcSEcCtD
Ceftazidime—Aplastic anaemia—Doxorubicin—sarcoma	0.00146	0.00351	CcSEcCtD
Ceftazidime—Thrombocytopenia—Thiotepa—sarcoma	0.00145	0.0035	CcSEcCtD
Ceftazidime—Leukopenia—Vincristine—sarcoma	0.00144	0.00348	CcSEcCtD
Ceftazidime—Thrombocytopenia—Dactinomycin—sarcoma	0.00144	0.00348	CcSEcCtD
Ceftazidime—Skin disorder—Thiotepa—sarcoma	0.00144	0.00347	CcSEcCtD
Ceftazidime—Erythema multiforme—Etoposide—sarcoma	0.00142	0.00342	CcSEcCtD
Ceftazidime—Coma—Doxorubicin—sarcoma	0.00142	0.00341	CcSEcCtD
Ceftazidime—Phlebitis—Epirubicin—sarcoma	0.00141	0.0034	CcSEcCtD
Ceftazidime—Leukopenia—Mitoxantrone—sarcoma	0.00141	0.00339	CcSEcCtD
Ceftazidime—Thrombophlebitis—Epirubicin—sarcoma	0.00141	0.00338	CcSEcCtD
Ceftazidime—Convulsion—Vincristine—sarcoma	0.0014	0.00337	CcSEcCtD
Ceftazidime—Flushing—Etoposide—sarcoma	0.00139	0.00336	CcSEcCtD
Ceftazidime—Hepatic function abnormal—Epirubicin—sarcoma	0.00139	0.00335	CcSEcCtD
Ceftazidime—Angiopathy—Etoposide—sarcoma	0.00136	0.00328	CcSEcCtD
Ceftazidime—Convulsion—Mitoxantrone—sarcoma	0.00136	0.00328	CcSEcCtD
Ceftazidime—Immune system disorder—Etoposide—sarcoma	0.00136	0.00327	CcSEcCtD
Ceftazidime—Paraesthesia—Thiotepa—sarcoma	0.00133	0.00321	CcSEcCtD
Ceftazidime—Anaphylactic shock—Vincristine—sarcoma	0.00132	0.00317	CcSEcCtD
Ceftazidime—Phlebitis—Doxorubicin—sarcoma	0.00131	0.00315	CcSEcCtD
Ceftazidime—Hot flush—Epirubicin—sarcoma	0.0013	0.00313	CcSEcCtD
Ceftazidime—Thrombophlebitis—Doxorubicin—sarcoma	0.0013	0.00313	CcSEcCtD
Ceftazidime—Nervous system disorder—Vincristine—sarcoma	0.00129	0.00311	CcSEcCtD
Ceftazidime—Menopausal symptoms—Epirubicin—sarcoma	0.00129	0.00311	CcSEcCtD
Ceftazidime—Thrombocytopenia—Vincristine—sarcoma	0.00129	0.00311	CcSEcCtD
Ceftazidime—Hepatic function abnormal—Doxorubicin—sarcoma	0.00129	0.0031	CcSEcCtD
Ceftazidime—Anaphylactic shock—Mitoxantrone—sarcoma	0.00128	0.00309	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Thiotepa—sarcoma	0.00128	0.00309	CcSEcCtD
Ceftazidime—Dysgeusia—Etoposide—sarcoma	0.00128	0.00308	CcSEcCtD
Ceftazidime—Renal impairment—Epirubicin—sarcoma	0.00128	0.00308	CcSEcCtD
Ceftazidime—Pain—Thiotepa—sarcoma	0.00127	0.00306	CcSEcCtD
Ceftazidime—Pain—Dactinomycin—sarcoma	0.00126	0.00304	CcSEcCtD
Ceftazidime—Thrombocytopenia—Mitoxantrone—sarcoma	0.00126	0.00302	CcSEcCtD
Ceftazidime—Skin disorder—Mitoxantrone—sarcoma	0.00125	0.003	CcSEcCtD
Ceftazidime—Lethargy—Epirubicin—sarcoma	0.00124	0.00299	CcSEcCtD
Ceftazidime—Hypotension—Vincristine—sarcoma	0.00123	0.00296	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Thiotepa—sarcoma	0.00121	0.00292	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Dactinomycin—sarcoma	0.00121	0.0029	CcSEcCtD
Ceftazidime—Hot flush—Doxorubicin—sarcoma	0.0012	0.0029	CcSEcCtD
Ceftazidime—Hypotension—Mitoxantrone—sarcoma	0.0012	0.00289	CcSEcCtD
Ceftazidime—Menopausal symptoms—Doxorubicin—sarcoma	0.00119	0.00287	CcSEcCtD
Ceftazidime—Renal impairment—Doxorubicin—sarcoma	0.00118	0.00285	CcSEcCtD
Ceftazidime—Paraesthesia—Vincristine—sarcoma	0.00118	0.00285	CcSEcCtD
Ceftazidime—Urticaria—Thiotepa—sarcoma	0.00118	0.00284	CcSEcCtD
Ceftazidime—Abdominal pain—Thiotepa—sarcoma	0.00117	0.00283	CcSEcCtD
Ceftazidime—Body temperature increased—Thiotepa—sarcoma	0.00117	0.00283	CcSEcCtD
Ceftazidime—Leukopenia—Etoposide—sarcoma	0.00117	0.00282	CcSEcCtD
Ceftazidime—Abdominal pain—Dactinomycin—sarcoma	0.00117	0.00281	CcSEcCtD
Ceftazidime—Body temperature increased—Dactinomycin—sarcoma	0.00117	0.00281	CcSEcCtD
Ceftazidime—Paraesthesia—Mitoxantrone—sarcoma	0.00115	0.00277	CcSEcCtD
Ceftazidime—Lethargy—Doxorubicin—sarcoma	0.00115	0.00277	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Vincristine—sarcoma	0.00114	0.00274	CcSEcCtD
Ceftazidime—Convulsion—Etoposide—sarcoma	0.00113	0.00273	CcSEcCtD
Ceftazidime—Pain—Vincristine—sarcoma	0.00113	0.00271	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.00111	0.00266	CcSEcCtD
Ceftazidime—Pain—Mitoxantrone—sarcoma	0.0011	0.00264	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Epirubicin—sarcoma	0.0011	0.00264	CcSEcCtD
Ceftazidime—Hypersensitivity—Thiotepa—sarcoma	0.00109	0.00264	CcSEcCtD
Ceftazidime—Hypersensitivity—Dactinomycin—sarcoma	0.00109	0.00262	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Vincristine—sarcoma	0.00108	0.00259	CcSEcCtD
Ceftazidime—Anaphylactic shock—Etoposide—sarcoma	0.00107	0.00257	CcSEcCtD
Ceftazidime—Pruritus—Thiotepa—sarcoma	0.00105	0.00253	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Mitoxantrone—sarcoma	0.00105	0.00253	CcSEcCtD
Ceftazidime—Thrombocytopenia—Etoposide—sarcoma	0.00104	0.00252	CcSEcCtD
Ceftazidime—Eosinophilia—Epirubicin—sarcoma	0.00104	0.00251	CcSEcCtD
Ceftazidime—Abdominal pain—Vincristine—sarcoma	0.00104	0.00251	CcSEcCtD
Ceftazidime—Body temperature increased—Vincristine—sarcoma	0.00104	0.00251	CcSEcCtD
Ceftazidime—Skin disorder—Etoposide—sarcoma	0.00104	0.0025	CcSEcCtD
Ceftazidime—Urticaria—Mitoxantrone—sarcoma	0.00102	0.00245	CcSEcCtD
Ceftazidime—Diarrhoea—Thiotepa—sarcoma	0.00102	0.00245	CcSEcCtD
Ceftazidime—Abdominal pain—Mitoxantrone—sarcoma	0.00101	0.00244	CcSEcCtD
Ceftazidime—Body temperature increased—Mitoxantrone—sarcoma	0.00101	0.00244	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Doxorubicin—sarcoma	0.00101	0.00244	CcSEcCtD
Ceftazidime—Diarrhoea—Dactinomycin—sarcoma	0.00101	0.00243	CcSEcCtD
Ceftazidime—Pancytopenia—Epirubicin—sarcoma	0.000999	0.00241	CcSEcCtD
Ceftazidime—Hypotension—Etoposide—sarcoma	0.000997	0.0024	CcSEcCtD
Ceftazidime—Neutropenia—Epirubicin—sarcoma	0.000984	0.00237	CcSEcCtD
Ceftazidime—Dizziness—Thiotepa—sarcoma	0.000982	0.00237	CcSEcCtD
Ceftazidime—Hypersensitivity—Vincristine—sarcoma	0.000971	0.00234	CcSEcCtD
Ceftazidime—Eosinophilia—Doxorubicin—sarcoma	0.000964	0.00232	CcSEcCtD
Ceftazidime—Paraesthesia—Etoposide—sarcoma	0.000958	0.00231	CcSEcCtD
Ceftazidime—Hypersensitivity—Mitoxantrone—sarcoma	0.000945	0.00228	CcSEcCtD
Ceftazidime—Vomiting—Thiotepa—sarcoma	0.000945	0.00227	CcSEcCtD
Ceftazidime—Infestation NOS—Epirubicin—sarcoma	0.000938	0.00226	CcSEcCtD
Ceftazidime—Infestation—Epirubicin—sarcoma	0.000938	0.00226	CcSEcCtD
Ceftazidime—Vomiting—Dactinomycin—sarcoma	0.000937	0.00226	CcSEcCtD
Ceftazidime—Rash—Thiotepa—sarcoma	0.000937	0.00226	CcSEcCtD
Ceftazidime—Dermatitis—Thiotepa—sarcoma	0.000936	0.00225	CcSEcCtD
Ceftazidime—Headache—Thiotepa—sarcoma	0.000931	0.00224	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Epirubicin—sarcoma	0.00093	0.00224	CcSEcCtD
Ceftazidime—Rash—Dactinomycin—sarcoma	0.00093	0.00224	CcSEcCtD
Ceftazidime—Pancytopenia—Doxorubicin—sarcoma	0.000924	0.00223	CcSEcCtD
Ceftazidime—Renal failure—Epirubicin—sarcoma	0.000922	0.00222	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Etoposide—sarcoma	0.000921	0.00222	CcSEcCtD
Ceftazidime—Jaundice—Epirubicin—sarcoma	0.000914	0.0022	CcSEcCtD
Ceftazidime—Pain—Etoposide—sarcoma	0.000913	0.0022	CcSEcCtD
Ceftazidime—Neutropenia—Doxorubicin—sarcoma	0.00091	0.00219	CcSEcCtD
Ceftazidime—Diarrhoea—Vincristine—sarcoma	0.000901	0.00217	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Epirubicin—sarcoma	0.000887	0.00214	CcSEcCtD
Ceftazidime—Nausea—Thiotepa—sarcoma	0.000882	0.00212	CcSEcCtD
Ceftazidime—Diarrhoea—Mitoxantrone—sarcoma	0.000878	0.00211	CcSEcCtD
Ceftazidime—Nausea—Dactinomycin—sarcoma	0.000876	0.00211	CcSEcCtD
Ceftazidime—Agranulocytosis—Epirubicin—sarcoma	0.000875	0.00211	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Etoposide—sarcoma	0.000873	0.0021	CcSEcCtD
Ceftazidime—Dizziness—Vincristine—sarcoma	0.000871	0.0021	CcSEcCtD
Ceftazidime—Infestation NOS—Doxorubicin—sarcoma	0.000868	0.00209	CcSEcCtD
Ceftazidime—Infestation—Doxorubicin—sarcoma	0.000868	0.00209	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Doxorubicin—sarcoma	0.00086	0.00207	CcSEcCtD
Ceftazidime—Renal failure—Doxorubicin—sarcoma	0.000853	0.00205	CcSEcCtD
Ceftazidime—Urticaria—Etoposide—sarcoma	0.000848	0.00204	CcSEcCtD
Ceftazidime—Haemoglobin—Epirubicin—sarcoma	0.000846	0.00204	CcSEcCtD
Ceftazidime—Jaundice—Doxorubicin—sarcoma	0.000846	0.00204	CcSEcCtD
Ceftazidime—Abdominal pain—Etoposide—sarcoma	0.000844	0.00203	CcSEcCtD
Ceftazidime—Body temperature increased—Etoposide—sarcoma	0.000844	0.00203	CcSEcCtD
Ceftazidime—Haemorrhage—Epirubicin—sarcoma	0.000842	0.00203	CcSEcCtD
Ceftazidime—Vomiting—Vincristine—sarcoma	0.000838	0.00202	CcSEcCtD
Ceftazidime—Rash—Vincristine—sarcoma	0.000831	0.002	CcSEcCtD
Ceftazidime—Dermatitis—Vincristine—sarcoma	0.00083	0.002	CcSEcCtD
Ceftazidime—Headache—Vincristine—sarcoma	0.000825	0.00199	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Doxorubicin—sarcoma	0.000821	0.00198	CcSEcCtD
Ceftazidime—Vomiting—Mitoxantrone—sarcoma	0.000816	0.00196	CcSEcCtD
Ceftazidime—Agranulocytosis—Doxorubicin—sarcoma	0.00081	0.00195	CcSEcCtD
Ceftazidime—Rash—Mitoxantrone—sarcoma	0.000809	0.00195	CcSEcCtD
Ceftazidime—Dermatitis—Mitoxantrone—sarcoma	0.000808	0.00195	CcSEcCtD
Ceftazidime—Headache—Mitoxantrone—sarcoma	0.000804	0.00193	CcSEcCtD
Ceftazidime—Erythema multiforme—Epirubicin—sarcoma	0.000796	0.00192	CcSEcCtD
Ceftazidime—Hypersensitivity—Etoposide—sarcoma	0.000786	0.00189	CcSEcCtD
Ceftazidime—Haemoglobin—Doxorubicin—sarcoma	0.000783	0.00189	CcSEcCtD
Ceftazidime—Nausea—Vincristine—sarcoma	0.000782	0.00188	CcSEcCtD
Ceftazidime—Flushing—Epirubicin—sarcoma	0.000781	0.00188	CcSEcCtD
Ceftazidime—Haemorrhage—Doxorubicin—sarcoma	0.000779	0.00188	CcSEcCtD
Ceftazidime—Angiopathy—Epirubicin—sarcoma	0.000764	0.00184	CcSEcCtD
Ceftazidime—Nausea—Mitoxantrone—sarcoma	0.000762	0.00183	CcSEcCtD
Ceftazidime—Immune system disorder—Epirubicin—sarcoma	0.00076	0.00183	CcSEcCtD
Ceftazidime—Pruritus—Etoposide—sarcoma	0.000755	0.00182	CcSEcCtD
Ceftazidime—Erythema multiforme—Doxorubicin—sarcoma	0.000737	0.00177	CcSEcCtD
Ceftazidime—Diarrhoea—Etoposide—sarcoma	0.00073	0.00176	CcSEcCtD
Ceftazidime—Flushing—Doxorubicin—sarcoma	0.000723	0.00174	CcSEcCtD
Ceftazidime—Dysgeusia—Epirubicin—sarcoma	0.000718	0.00173	CcSEcCtD
Ceftazidime—Angiopathy—Doxorubicin—sarcoma	0.000707	0.0017	CcSEcCtD
Ceftazidime—Dizziness—Etoposide—sarcoma	0.000706	0.0017	CcSEcCtD
Ceftazidime—Immune system disorder—Doxorubicin—sarcoma	0.000704	0.00169	CcSEcCtD
Ceftazidime—Vision blurred—Epirubicin—sarcoma	0.000691	0.00166	CcSEcCtD
Ceftazidime—Vomiting—Etoposide—sarcoma	0.000678	0.00163	CcSEcCtD
Ceftazidime—Agitation—Epirubicin—sarcoma	0.000674	0.00162	CcSEcCtD
Ceftazidime—Rash—Etoposide—sarcoma	0.000673	0.00162	CcSEcCtD
Ceftazidime—Dermatitis—Etoposide—sarcoma	0.000672	0.00162	CcSEcCtD
Ceftazidime—Headache—Etoposide—sarcoma	0.000668	0.00161	CcSEcCtD
Ceftazidime—Dysgeusia—Doxorubicin—sarcoma	0.000664	0.0016	CcSEcCtD
Ceftazidime—Leukopenia—Epirubicin—sarcoma	0.000656	0.00158	CcSEcCtD
Ceftazidime—Vision blurred—Doxorubicin—sarcoma	0.000639	0.00154	CcSEcCtD
Ceftazidime—Convulsion—Epirubicin—sarcoma	0.000635	0.00153	CcSEcCtD
Ceftazidime—Nausea—Etoposide—sarcoma	0.000634	0.00153	CcSEcCtD
Ceftazidime—Agitation—Doxorubicin—sarcoma	0.000623	0.0015	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.00062	0.00149	CcSEcCtD
Ceftazidime—Leukopenia—Doxorubicin—sarcoma	0.000607	0.00146	CcSEcCtD
Ceftazidime—Anaphylactic shock—Epirubicin—sarcoma	0.000598	0.00144	CcSEcCtD
Ceftazidime—Convulsion—Doxorubicin—sarcoma	0.000588	0.00141	CcSEcCtD
Ceftazidime—Nervous system disorder—Epirubicin—sarcoma	0.000587	0.00141	CcSEcCtD
Ceftazidime—Thrombocytopenia—Epirubicin—sarcoma	0.000586	0.00141	CcSEcCtD
Ceftazidime—Skin disorder—Epirubicin—sarcoma	0.000581	0.0014	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000573	0.00138	CcSEcCtD
Ceftazidime—Hypotension—Epirubicin—sarcoma	0.000559	0.00135	CcSEcCtD
Ceftazidime—Anaphylactic shock—Doxorubicin—sarcoma	0.000553	0.00133	CcSEcCtD
Ceftazidime—Nervous system disorder—Doxorubicin—sarcoma	0.000543	0.00131	CcSEcCtD
Ceftazidime—Thrombocytopenia—Doxorubicin—sarcoma	0.000542	0.0013	CcSEcCtD
Ceftazidime—Skin disorder—Doxorubicin—sarcoma	0.000538	0.00129	CcSEcCtD
Ceftazidime—Paraesthesia—Epirubicin—sarcoma	0.000537	0.00129	CcSEcCtD
Ceftazidime—Hypotension—Doxorubicin—sarcoma	0.000517	0.00125	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Epirubicin—sarcoma	0.000516	0.00124	CcSEcCtD
Ceftazidime—Pain—Epirubicin—sarcoma	0.000512	0.00123	CcSEcCtD
Ceftazidime—Paraesthesia—Doxorubicin—sarcoma	0.000497	0.0012	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Epirubicin—sarcoma	0.000489	0.00118	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000478	0.00115	CcSEcCtD
Ceftazidime—Urticaria—Epirubicin—sarcoma	0.000475	0.00114	CcSEcCtD
Ceftazidime—Pain—Doxorubicin—sarcoma	0.000473	0.00114	CcSEcCtD
Ceftazidime—Body temperature increased—Epirubicin—sarcoma	0.000473	0.00114	CcSEcCtD
Ceftazidime—Abdominal pain—Epirubicin—sarcoma	0.000473	0.00114	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Doxorubicin—sarcoma	0.000453	0.00109	CcSEcCtD
Ceftazidime—Hypersensitivity—Epirubicin—sarcoma	0.000441	0.00106	CcSEcCtD
Ceftazidime—Urticaria—Doxorubicin—sarcoma	0.00044	0.00106	CcSEcCtD
Ceftazidime—Body temperature increased—Doxorubicin—sarcoma	0.000438	0.00105	CcSEcCtD
Ceftazidime—Abdominal pain—Doxorubicin—sarcoma	0.000438	0.00105	CcSEcCtD
Ceftazidime—Pruritus—Epirubicin—sarcoma	0.000423	0.00102	CcSEcCtD
Ceftazidime—Diarrhoea—Epirubicin—sarcoma	0.000409	0.000985	CcSEcCtD
Ceftazidime—Hypersensitivity—Doxorubicin—sarcoma	0.000408	0.000982	CcSEcCtD
Ceftazidime—Dizziness—Epirubicin—sarcoma	0.000396	0.000952	CcSEcCtD
Ceftazidime—Pruritus—Doxorubicin—sarcoma	0.000392	0.000943	CcSEcCtD
Ceftazidime—Vomiting—Epirubicin—sarcoma	0.00038	0.000916	CcSEcCtD
Ceftazidime—Diarrhoea—Doxorubicin—sarcoma	0.000379	0.000912	CcSEcCtD
Ceftazidime—Rash—Epirubicin—sarcoma	0.000377	0.000908	CcSEcCtD
Ceftazidime—Dermatitis—Epirubicin—sarcoma	0.000377	0.000907	CcSEcCtD
Ceftazidime—Headache—Epirubicin—sarcoma	0.000375	0.000902	CcSEcCtD
Ceftazidime—Dizziness—Doxorubicin—sarcoma	0.000366	0.000881	CcSEcCtD
Ceftazidime—Nausea—Epirubicin—sarcoma	0.000355	0.000855	CcSEcCtD
Ceftazidime—Vomiting—Doxorubicin—sarcoma	0.000352	0.000847	CcSEcCtD
Ceftazidime—Rash—Doxorubicin—sarcoma	0.000349	0.00084	CcSEcCtD
Ceftazidime—Dermatitis—Doxorubicin—sarcoma	0.000349	0.000839	CcSEcCtD
Ceftazidime—Headache—Doxorubicin—sarcoma	0.000347	0.000835	CcSEcCtD
Ceftazidime—Nausea—Doxorubicin—sarcoma	0.000329	0.000792	CcSEcCtD
